• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human IFN alpha 2B protein

Activity

Typically ≤ 0.12 ng/mL

Specific Activity

minimally 5.00 x 107 IU/mg

Species Reactivity

human

Purity

>95%

Cat No : HZ-1072

Print datasheet

Synonyms

IFN alpha 2, IFNA, IFNA2, INFA2, Interferon alpha 2, Interferon alpha A, interferon, alpha 2, LeIF A

Validation Data Gallery

  • Purity of recombinant human IFN alpha 2B was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

    Purity of recombinant human IFN alpha 2B was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

  • Recombinant human IFN alpha 2B (HZ-1072) dose-dependently inhibits growth of the TF-1 cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. TF-1 cells were treated with increasing concentrations of recombinant IFN alpha 2B for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 0.004-0.020 ng/mL​.

    Recombinant human IFN alpha 2B (HZ-1072) dose-dependently inhibits growth of the TF-1 cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. TF-1 cells were treated with increasing concentrations of recombinant IFN alpha 2B for 72 hours. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 0.004-0.020 ng/mL​.

Technical Specifications

GeneID 3440
Species Human
Expression HEK293
Activity Typically ≤ 0.12 ng/mL
Specific Activityminimally 5.00 x 107 IU/mg
Purity >95%
Endotoxin<1 EU/μg
Accession NumberP01563
Molecular Mass 18 to 22 kDa reduced, 16 to 18 kDa non-reduced, monomer, glycosylated
Formulation 1x PBS, See Certificate of Analysis for details
Species Reactivity human

Stability and Reconstitution

Stability and StorageProduct FormTemperature ConditionsStorage Time
(From Date of Receipt)
Lyophilized-20°C to -80°CUntil Expiry Date
LyophilizedRoom Temperature2 weeks
Reconstituted as per CofA-20°C to -80°C6 months
Reconstituted as per CofA4°C1 week
Avoid repeated freeze-thaw cycles.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1x PBS pH 7.4 containing 0.1% endotoxin-free recombinant human serum albumin (HSA). Gently swirl or tap vial to mix.

Background

Interferon alpha 2 is a type 1 interferon secreted by virus-infected cells to protect surrounding cells from the pathogen. Recombinant human interferon alpha 2 has been approved for therapeutic application in a range of human oncological and viral diseases. Three Interferon alpha 2 subvariants (2A, 2B, 2C) differ by only one or two amino acids at positions 23 and/or 34 of the mature protein (PMID: 25982860; 10672347; 1694761)

Synonyms

IFN alpha 2, IFNA, IFNA2, INFA2, Interferon alpha 2, Interferon alpha A, interferon, alpha 2, LeIF A

Publications

SpeciesTitle
human

Cancer Sci

Combination of tumor necrosis factor-α and epidermal growth factor induces the adrenergic-to-mesenchymal transdifferentiation in SH-SY5Y neuroblastoma cells.

Authors - Yue Huang
View Article

Antiviral Res

Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.

Authors - Takashi Nishiyama
View Article
human

J Virol Methods

Screening of novel drugs for inhibiting hepatitis E virus replication.

Authors - Takashi Nishiyama
View Article
human

EMBO Mol Med

SLE serum induces altered goblet cell differentiation and leakiness in human intestinal organoids

Authors - Inga Viktoria Hensel
View Article